Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.53 |
| ▸ | CCR2 | P41597 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3149381 | 0.91 | DRD4 (0.52) | DRD4CCR2DRD2DRD1SLC6A4 | |
| SCHEMBL3154562 | 0.90 | DRD4 (0.54) | DRD4DRD2HTR1AHSD17B10OPRM1 | |
| SCHEMBL3153306 | 0.88 | DRD2 (0.48) | DRD4CCR2DRD2DRD1 | |
| SCHEMBL3140843 | 0.88 | DRD4 (0.51) | DRD4CCR2DRD2HSD17B10OPRM1 | |
| SCHEMBL3150189 | 0.88 | HTR1A (0.53) | DRD4CCR2HTR1A | |
| SCHEMBL3139288 | 0.83 | DRD4 (0.53) | DRD4DRD2HTR1AHSD17B10 | |
| SCHEMBL3141051 | 0.82 | SLC6A4 (0.47) | DRD4DRD2OPRM1SLC6A4 | |
| SCHEMBL3149887 | 0.81 | CCR2 (0.55) | DRD4CCR2 | |
| SCHEMBL3148959 | 0.80 | DRD4 (0.52) | DRD4DRD2HSD17B10SLC6A4 | |
| SCHEMBL3149836 | 0.80 | CCR2 (0.50) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | DRD4 820/4885CCR2 417/4885DRD2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.